The Cures Work. The Business Model Doesn't.

Sickle cell disease has tortured human beings for as long as we have been able to name it. A single misspelled letter in the genetic code warps red blood cells into rigid crescents that clog vessels, starve organs of oxygen, and trigger pain crises severe enough to require hospitalization. For most of the 20th century, the only treatments were blood transfusions and a chemotherapy drug repurposed to coax the body into making fetal hemoglobin. Then, in December 2023, the U.S. Food and Drug Administration approved Casgevy — the first medicine in history to use CRISPR gene editing to treat a human disease. One infusion. A functional cure.

It worked. That was never really in doubt by the time it crossed the regulatory finish line. What almost nobody priced correctly is what came next.

More than two years after approval, roughly 60 patients worldwide have been treated with Casgevy. Not 60,000. Sixty. Across the United States, Europe, and the Middle East combined. A therapy that cures one of the most studied genetic diseases on the planet — a disease that afflicts roughly 100,000 Americans and millions globally — has reached a number of patients you could fit on a city bus.

This is the central paradox of the gene-editing era, and it is the most important thing investors in the space need to understand. The science problem is solved. The business model that follows is not. And the gap between those two facts is where the next decade of money in genetic medicine will be won and lost.

A Cure Is Not a Product

The pharmaceutical industry is built on a specific economic engine: develop a molecule, win approval, and then sell it to the same patient, every month, for years or decades. Chronic disease is, coldly stated, a recurring-revenue business. A statin, an inhaler, a daily pill for blood pressure — these are subscriptions the body can't cancel.

A one-time cure detonates that model. You spend a billion-plus dollars and fifteen years developing a therapy, and then you get to bill each patient exactly once. To make the math work, the price has to be enormous: Casgevy lists at $2.2 million, and bluebird bio's competing sickle cell therapy, Lyfgenia, at $3.1 million. Those numbers aren't greed so much as arithmetic — they're a lifetime of avoided transfusions, hospitalizations, and lost productivity, compressed into a single invoice.

But a $2.2 million invoice creates problems that don't exist for a $200 prescription.

The payer problem. An insurer pays $2.2 million today for a benefit that accrues over thirty years — and in America's fragmented insurance system, the patient may well switch plans long before that. Why should one insurer foot the entire upfront bill so a competitor reaps the downstream savings? This misalignment quietly throttles uptake even where coverage technically exists. About 90% of U.S. sickle cell patients now have reimbursed access on paper. The infusions still aren't happening at anything like that rate.

The delivery problem. Casgevy isn't a shot. It requires harvesting a patient's own stem cells, editing them in a manufacturing facility, and then — critically — wiping out the patient's existing bone marrow with busulfan, a brutal conditioning chemotherapy, before reinfusing the edited cells. The process can take the better part of a year, demands a specialized treatment center, and carries real risks including infertility. Some hospitals have simply declined to offer it, citing upfront cost, care coordination, and the burden of long-term follow-up.

The manufacturing problem. Every patient's cells are edited individually. This isn't a factory stamping out identical pills; it's artisanal biology at industrial prices, and it does not scale gracefully.

The Company That Hit the Wall First

If you want to see where a broken business model ends, look at bluebird bio — once the most celebrated name in gene therapy.

bluebird brought three gene therapies to market. The science was breathtaking. The commercial reality was a slow, brutally expensive grind: by late 2024, only 57 patients had started treatment across all three products combined, each carrying its own manufacturing line, treatment-center network, and reimbursement fight. The company burned cash faster than it could book revenue.

In February 2025, private equity firms Carlyle and SK Capital agreed to take bluebird private for $3 a share — a humiliating price for a company once valued in the billions. The buyout closed in June 2025. A gene therapy pioneer, ending its public life as a distressed asset.

The lesson markets are still digesting: in genetic medicine, scientific success and commercial success are almost entirely different problems. BioMarin already withdrew its hemophilia A gene therapy over weak sales. The graveyard is filling up with cures that nobody could figure out how to sell.

This is where the analysis gets actionable. AlphaBriefing members get the full investment framework — scenarios, positioning, and the bottom line.

Subscribe to AlphaBriefing — Free, Member, and Paid tiers available.